AZ: very cheap trick to fool innovators.

AstraZeneca plc (LSE:AZN; NYSE:AZN) launched its Open Innovation website listing programs available for partnering and inviting proposals for further development. At launch, the website provides preclinical and clinical data and potential disease areas for 46 compounds, including discontinued programs and new compounds remaining in the pharma's pipeline for which AZ is seeking partners for new indications.

The website also includes a route for interested parties to submit proposals to AZ for grants of up to $100,000 for target validation partnerships; and an "R&D Challenges" section where the pharma plans to crowd-source solutions to problems. In May, AstraZeneca plans to post more information about a discovery program that will provide screening assays and other assistance to external investigators while allowing the external partner to retain IP to discovered compounds.

From here:http://www.biocentury.com/dailynews/company/2014-03-25/astrazeneca-puts-programs-for-partnering-online